Cargando…
PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431483/ http://dx.doi.org/10.1097/01.HS9.0000851228.41662.2b |
| _version_ | 1784780068193566720 |
|---|---|
| author | Sharp, A. Williams, A. Blagden, S. Plummer, R. Hochhauser, D. Krebs, M. G. Pacey, S. Evans, J. Whelan, S. Nandakumar, S. Rogers, S. Jameson, K. L. Basile, F. G. de Bono, J. Arkenau, H.-T. |
| author_facet | Sharp, A. Williams, A. Blagden, S. Plummer, R. Hochhauser, D. Krebs, M. G. Pacey, S. Evans, J. Whelan, S. Nandakumar, S. Rogers, S. Jameson, K. L. Basile, F. G. de Bono, J. Arkenau, H.-T. |
| author_sort | Sharp, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431483 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94314832022-08-31 PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL Sharp, A. Williams, A. Blagden, S. Plummer, R. Hochhauser, D. Krebs, M. G. Pacey, S. Evans, J. Whelan, S. Nandakumar, S. Rogers, S. Jameson, K. L. Basile, F. G. de Bono, J. Arkenau, H.-T. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431483/ http://dx.doi.org/10.1097/01.HS9.0000851228.41662.2b Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Sharp, A. Williams, A. Blagden, S. Plummer, R. Hochhauser, D. Krebs, M. G. Pacey, S. Evans, J. Whelan, S. Nandakumar, S. Rogers, S. Jameson, K. L. Basile, F. G. de Bono, J. Arkenau, H.-T. PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL |
| title | PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL |
| title_full | PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL |
| title_fullStr | PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL |
| title_full_unstemmed | PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL |
| title_short | PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL |
| title_sort | pb2099: a first-in-human phase 1 trial of nx-1607, a first-in-class oral cbl-b inhibitor, in patients with advanced malignancies including richter transformation dlbcl |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431483/ http://dx.doi.org/10.1097/01.HS9.0000851228.41662.2b |
| work_keys_str_mv | AT sharpa pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT williamsa pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT blagdens pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT plummerr pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT hochhauserd pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT krebsmg pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT paceys pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT evansj pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT whelans pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT nandakumars pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT rogerss pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT jamesonkl pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT basilefg pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT debonoj pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl AT arkenauht pb2099afirstinhumanphase1trialofnx1607afirstinclassoralcblbinhibitorinpatientswithadvancedmalignanciesincludingrichtertransformationdlbcl |